Skip to main content

Month: March 2024

WSP Acquires Communica, Reinforcing Its Indigenous and Stakeholder Engagement Services in Canada

MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) — WSP Global Inc. (TSX: WSP) (“WSP” or the “Corporation”) is pleased to announce it has completed the acquisition of Communica Public Affairs Inc. (“Communica”), one of Canada’s leading Indigenous and stakeholder engagement and information management consulting firms. Founded in 2002, Communica is recognized for its collaborative approach and its ability to deliver authentic, open, and transparent stakeholder and wider community engagement, including with Indigenous communities. This acquisition reinforces WSP’s commitment to delivering impactful projects for communities and enhances its ability to respond to the increasing demand for stakeholder engagement and information management services. These services are integral to the success of projects in all sectors and markets across Canada...

Continue reading

Prosper Gold Provides Update on Option Agreement to Acquire the Kaza and Northstar Properties

VANCOUVER, British Columbia, March 21, 2024 (GLOBE NEWSWIRE) — Prosper Gold Corp. (“Prosper Gold” or the “Company”) (TSXV:PGX) is pleased to report on the status of its option to acquire a 100% interest in the Kaza and Northstar properties (the “Option”), pursuant to a definitive option agreement (the “Option Agreement”) with several individuals (collectively, the “Optionors”), as previously announced on February 20, 2024 (the “Initial Press Release”). The Company received conditional approval of the transaction contemplated by the Option Agreement (the “Transaction”) from the TSX Venture Exchange (the “TSXV”) on March 8, 2024, which requires the Company to provide an update on the status of the Transaction 30 days following the Initial Press Release. The Company satisfied the first condition to exercise the Option by issuing 150,000...

Continue reading

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 PHILADELPHIA, March 21, 2024 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the year ended December 31, 2023, and reported on recent and upcoming business highlights. “During the fourth quarter of 2023, Context continued to advance our lead clinical candidate, CTIM-76, a Claudin 6 (“CLDN6”) x CD3 bispecific antibody, toward a first-in-human clinical study. Preclinical data presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting highlighted the...

Continue reading

MiNK Reports Fourth Quarter and Year-End 2023 Results

Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancersAnnounced collaboration with Immunoscape for development of TCR-based therapies Published clinical data in Nature Communications and Oncogene demonstrating clinical activity of allo-iNKTs, agenT-797, in solid tumors and severe acute respiratory distressNEW YORK, March 21, 2024 (GLOBE NEWSWIRE) —  MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the fourth quarter and full-year 2023. MiNK executives will host a conference call and webcast...

Continue reading

Innovative Food Holdings, Inc. Reports Financial Results for Fourth Quarter and Fiscal Year 2023

Key Fiscal Year data points:Revenue of $72.2 million, -8.5% vs. 2022 Gross margin improved by 205 basis points to 24.3%, while adjusted gross margin improved by 232 basis points GAAP net loss from continuing operations of ($4.2 million) or ($0.08) per fully diluted share, compared to a 2022 loss of ($1.1 million) or ($0.02) per fully diluted share Adjusted net income from continuing operations of $1.1 million or $0.02 per fully diluted share, compared to a 2022 adjusted net loss of ($0.8 million) or ($0.02) per fully diluted share Adjusted EBITDA of $2.5 million, compared to $0.3 million last year Working Capital improved from a deficit of ($3.2 million) at the end of 2022 to a surplus of $5.0 million at the end of 2023, representing an increase of approximately $8.2 million The refinancing of company debt, USDA debt guarantee, and...

Continue reading

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET-SLE™ trials anticipated in 1H24; longer term follow-up on these and additional patients to be reported in 2H24 – – RESET-SSc™ (systemic sclerosis) and RESET-MG™ trials initial clinical data anticipated to be reported in 2H24 – – Rare Pediatric Disease designation granted by FDA for CABA-201 in juvenile dermatomyositis – – Cash runway into 1H26 with cash, cash equivalents and short-term investments of $241.2 million as of December 31, 2023 – PHILADELPHIA, March 21, 2024 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first...

Continue reading

Destination XL Group, Inc. Reports Fiscal 2023 Fourth Quarter and  Full-Year Financial Results

Full-Year Sales of $521.8 million, Net Income of $27.9 million, $0.43 EPS, Adjusted EBITDA of $55.9 million CANTON, Mass., March 21, 2024 (GLOBE NEWSWIRE) — Destination XL Group, Inc. (NASDAQ: DXLG), the largest integrated commerce specialty retailer of Big + Tall men’s clothing and shoes, today reported financial results for the fourth quarter and fiscal year 2023. Fourth Quarter HighlightsTotal sales for the 14-week fourth quarter were $137.1 million, down 4.7% from $143.9 million for the 13-week fourth quarter of fiscal 2022. Comparable sales for the fourth quarter decreased 10.1% as compared to the fourth quarter of fiscal 2022. Net income for the fourth quarter was $5.2 million, or $0.08 per diluted share, as compared to net income of $8.3 million, or $0.13 per diluted share, for the fourth quarter of fiscal 2022.  Results...

Continue reading

Winnebago Industries Reports Second Quarter Fiscal 2024 Results

— Delivers Solid Gross Margin of 15.0% Demonstrating Strength of Product Diversification andVariable Cost Structure — — Completes $350 Million Offering of Convertible Senior Notes for Refinancing 2025 Maturities — — Barletta Captures 7.9% Share of U.S. Aluminum Pontoon Market(1), up 80 Basis Points YoY — — Company Introduces Future Mid-Cycle Organic Growth Targets — EDEN PRAIRIE, Minn., March 21, 2024 (GLOBE NEWSWIRE) — Winnebago Industries, Inc. (NYSE: WGO), a leading outdoor lifestyle product manufacturer, today reported financial results for the fiscal 2024 second quarter ended February 24, 2024. Second Quarter Fiscal 2024 Financial SummaryRevenues of $703.6 millionGross profit of $105.3 million, representing 15.0% gross marginNet loss of $12.7 million, or $0.43 per share,...

Continue reading

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

$19 million revenue in 2023; $24 million projected revenue in 2024NexoBrid® commercially launched in U.S., Japan, IndiaPotential blockbuster EscharEx® to begin Phase III in the second half of 2024$42 million cash runway through profitability Conference call today, March 21 at 8:30am Eastern Time YAVNE, Israel, March 21, 2024 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. “2023 was an exceptional year for NexoBrid driven by new market launches, expanded indications, substantial new governmental grants, and increased global demand. Additionally, this lifesaving treatment was successfully battle-tested in real-life burn mass...

Continue reading

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median follow-up of 14.4 months; IMA203 was well tolerated Registration-enabling randomized Phase 2/3 trial for ACTengine® IMA203 GEN1 in 2L+ melanoma planned to begin in 2024 Next data update on IMA203 GEN1 and IMA203CD8 GEN2 planned for 2H 2024First clinical data updates for Immatics’ next-generation TCR Bispecifics, TCER® IMA401 (MAGEA4/8) and TCER® IMA402 (PRAME), from ongoing Phase 1 dose escalation trials planned for 2H 2024; updates to include details on safety, pharmacokinetics and initial anti-tumor activity In May 2023, Bristol Myers Squibb exercised first opt-in into the autologous cell therapy collaboration ($15 million option fee received)...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.